Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Beumont

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Journal of Hepatology|December 3, 2014
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studiesOliver Lenz, Thierry Verbinnen, Bart Fevery, et al.
Gastroenterology|June 25, 2011
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infectionsGraham R Foster, Christophe Hézode, Jean-Pierre Bronowicki, et al.
Health Science Reports|April 10, 2020
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT studyEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Gut|March 6, 2012
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1Lawrence Serfaty, Xavier Forns, Tobias Goeser, et al.
Hepatology (Baltimore, Md.)|July 19, 2012
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trialSandra De Meyer, Inge Dierynck, Anne Ghys, et al.
Clinical Pharmacology and Therapeutics|June 18, 2026
Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug-Resistant TuberculosisPauline Howell, Antonio Lombardi, William Brumskine, et al.
Gastroenterology|November 2, 2010
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis CPatrick Marcellin, Xavier Forns, Tobias Goeser, et al.
British Journal of Clinical Pharmacology|January 19, 2018
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medicationsFiona Marra, Christoph Höner Zu Siederdissen, Saye Khoo, et al.
AIDS Research and Human Retroviruses|October 9, 2007
Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized StudyCécile Goujard, Fabienne Marcellin, Houria Hendel-Chavez, et al.
Journal of Viral Hepatitis|December 13, 2019
Liver safety assessment in clinical trials of new agents for chronic hepatitis BRobert J Fontana, Mark I Avigan, Harry L A Janssen, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Journal of Hepatology|December 3, 2014
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studiesOliver Lenz, Thierry Verbinnen, Bart Fevery, et al.
Gastroenterology|June 25, 2011
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infectionsGraham R Foster, Christophe Hézode, Jean-Pierre Bronowicki, et al.
Health Science Reports|April 10, 2020
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT studyEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Gut|March 6, 2012
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1Lawrence Serfaty, Xavier Forns, Tobias Goeser, et al.
Hepatology (Baltimore, Md.)|July 19, 2012
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trialSandra De Meyer, Inge Dierynck, Anne Ghys, et al.
Clinical Pharmacology and Therapeutics|June 18, 2026
Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug-Resistant TuberculosisPauline Howell, Antonio Lombardi, William Brumskine, et al.
Gastroenterology|November 2, 2010
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis CPatrick Marcellin, Xavier Forns, Tobias Goeser, et al.
British Journal of Clinical Pharmacology|January 19, 2018
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medicationsFiona Marra, Christoph Höner Zu Siederdissen, Saye Khoo, et al.
AIDS Research and Human Retroviruses|October 9, 2007
Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized StudyCécile Goujard, Fabienne Marcellin, Houria Hendel-Chavez, et al.
Journal of Viral Hepatitis|December 13, 2019
Liver safety assessment in clinical trials of new agents for chronic hepatitis BRobert J Fontana, Mark I Avigan, Harry L A Janssen, et al.
Pageof 5